ArticleScientific reports2025
CCL3 correlates with ferroptosis in intervertebral disc degeneration and its prognostic significance.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IVDD) is a prevalent and debilitating condition associated with low back pain (LBP). Despite its significant impact, effective diagnostic markers for early-stage IVDD remain elusive. Recent research has implicated ferroptosis, a newly recognized form of programmed cell death, in the pathogenesis of IVDD, particularly involving disturbances in iron homeostasis. Additionally, the CC Chemokine Ligand 3 (CCL3) has been linked to macrophage migration and the progression of IVDD, yet its precise diagnostic and prognostic utility remains uncertain. This study aims to elucidate the underlying mechanisms of ferroptosis and the involvement of CCL3 in IVDD, with the objective of establishing their diagnostic and prognostic significance. By uncovering these mechanisms, novel biomarkers and therapeutic targets for the diagnosis and prognosis of IVDD may be identified. Single-cell sequencing data were acquired from the TCGA database, and a range of bioinformatics methods were employed for comprehensive analysis. Furthermore, validation experiments were conducted using in vitro techniques, including the analysis of human tissue samples, co-culture assays with neutralizing antibodies, quantitative real-time polymerase chain reaction (qRT-PCR), and Western blotting. Our findings suggest that CCL3 holds promise as a diagnostic and may was prognostic biomarker for IVDD. Validation experiments demonstrated that CCL3 functions via the pAMPK/AMPK pathway, thereby modulating apoptosis and impacting the progression of IVDD. Our study underscores the diagnostic and prognostic potential of CCL3 in patients with IVDD. Further investigations are warranted to explore therapeutic strategies targeting CCL3, ultimately enhancing the management of IVDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.